51 citations
,
March 2006 in “Bioorganic & Medicinal Chemistry” Newly made nicotinamide compounds could potentially treat cancer.
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride is more effective than finasteride for hair growth with similar side effects.
6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
Deleting Smad4 and PTEN genes in mice causes rapid, invasive stomach cancer.
1 citations
,
May 2022 in “Frontiers in Pharmacology” Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
91 citations
,
April 2006 in “PubMed” EGFR-targeting cancer drugs can cause skin rashes and other side effects.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
Patients with alopecia areata using Janus kinase inhibitors are not following lab monitoring guidelines.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
January 2024 in “Scripta Medica” Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
October 2009 in “Nature Reviews Urology”
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
August 2025 in “Ophthalmic Plastic and Reconstructive Surgery” Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.
5 citations
,
January 1991 in “Drugs of The Future”
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
83 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help children with alopecia areata regrow hair.
31 citations
,
October 2010 in “BMB Reports” L-threonate may help prevent balding by blocking a key protein.
1 citations
,
November 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
10 citations
,
October 2019 in “Iranian Biomedical Journal” Simvastatin helps hair follicle stem cells turn into skin cells.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
48 citations
,
March 2003 in “International Journal of Cancer” DMBT1 and galectin-3 may help suppress epithelial skin cancer.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.